Wire · opportunities
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Teva presented new post hoc data from the Phase 3 SOLARIS trial showing that its once-monthly subcutaneous injectable olanzapine (TEV-'749) achieved high rates of stabilization and remission with low relapse rates in adults with schizophrenia. The data also support safe switching from oral or short-acting injectable olanzapine to TEV-'749, ahead of an FDA approval decision expected in Q4 2026.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 18 Sep 2026 and 19 Sep 2026.
◆ ◆ The Wire takeaway
You can now position to serve patients shifting from daily oral olanzapine to a monthly injectable as the FDA nears approval. Switching treatments without losing efficacy opens a valuable patient segment that daily pills struggle to retain.
◆ Coverage
2 sources · first reported 18 Sep 2026 · latest 19 Sep 2026
◆ Related on Wire
◆ Topics